Publications

5491 Results

Residual circulating tumor DNA (ctDNA) after two months of therapy predicts progression-free and overall survival in patients treated on SWOG S1403 with afatinib +/- cetuximab

Authors
P Mack;M Redman;J Moon;S Goldberg;RS Herbst;M Melnick;Z Walther;F Hirsch;K Politi;K Kelly;D Gandara
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 9532); American Society of Clinical Oncology 2020 Annual Meeting, poster
Year
2020
Research Committee(s)
Lung
Study Number(s)
S1403

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605 (NCT #02844816)

Authors
P Black;C Tangen;P Singh;D McConkey;MS Lucia;W Lowrance;V Koshkin;K Stratton;T Bivalacqua;W Kassouf;S Porten;R Bangs;M Plets;S Lerner;I Thompson
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 5022); American Society of Clinical Oncology 2020 Annual Meeting, poster discussion
Year
2020
Research Committee(s)
Genitourinary
Study Number(s)
S1605

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: a Secondary Analysis of SWOG S0816

Authors
CS Ha;M Leblanc;H Schoder;C Pinnix;E Brem;N Bartlett;AM Evens;ED Hsi;L Rimsza;JP Leonard;BS Kahl;H Li;SM Smith;LS Constine;JW Friedberg
Journal / Conference
Leukemia & Lymphoma Oct;61(10):2442-2447
Year
2020
Research Committee(s)
Lymphoma
PMID
PMID32452714
Study Number(s)
S0816

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel

Authors
PN Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;P Twardowski;D Quinn;N Vogelzang;I Thompson
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 5523); American Society of Clinical Oncology 2020 Annual Meeting, poster
Year
2020
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide

Authors
A Goldkorn;C Tangen;M Plets;G Morrison;A Cunha;T Xu;J Pinski;S Ingles;T Triche;G MacVicar;A Crispino;D McConkey;PN Lara;M Hussain;D Quinn;N Vogelzang;I Thompson;N Agarwal
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 5506); American Society of Clinical Oncology 2020 Annual Meeting, oral
Year
2020
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702

Authors
J Meyerhardt;Q Shi;C Fuchs;D Niedzwiecki;T Zemla;P Kumthekar;K Guthrie;F Couture;JP Kuebler;J Bendell;P Kumar;D Lewis;B Tan;M Bertagnolli;A Grothey;H Hochster;R Goldberg;A Venook;CD Blanke;AF Shields
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 4003);American Society of Clinical Oncology Annual Meeting (5/29/2020 - 6/2/2020, Chicago, IL), oral
Year
2020
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Association of Prior immune anti-PD-1 antibody therapy with longer progression free survival in patients treated with intermittent versus continuous dabrafenib and trametinib: a post-hoc analysis of S1320

Authors
A Algazi;M Othus;A Daud;J Mehnert;T-G Truong;R Conry;K Kendra;GC Doolittle;JI Clark;M Messino;DF Moore;C Lao;B Faller;R Govindarajan;A Harker-Murray;L Dreisbach;J Moon;K Grossmann;R Lo;A Ribas
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 10039); American Society of Clinical Oncology Annual Meeting (5/29/2020 - 6/2/2020, Chicago, IL), poster
Year
2020
Research Committee(s)
Melanoma
Study Number(s)
S1320

Carfilzomib, lenalidomide and dexamethasone (KRd) versus Bortezomib, lenalidomide and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase 3 trial

Authors
S Kumar;S Jacobus;A Cohen;M Weiss;N Callander;A Singh;T Parker;A Menter;A Yang;B Parsons;P Kumar;P Kappor;A Rosenberg;J Zonder;E Faber;S Lonial;P Richardson;R Orlowski;S Rajkumar
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr LBA3); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), oral, plenary
Year
2020
Research Committee(s)
Myeloma
Study Number(s)
CTSU/E1A11

A randomized Phase Ill trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo Stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108)

Authors
S Khan;F Zhao;L Solin;L Goldstein;D Cella;M Basik;M Golshan;T Julian;B Pockaj;C Lee;W Razaq;J Sparano;G Babiera;I Dy;S Jain;P Silverman;C Fisher;A Tevaarwerk;L Wagner;G Sledge
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr LBA2); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), oral, plenary
Year
2020
Research Committee(s)
Breast
Study Number(s)
CTSU/E2108

Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 1118, IIIC, Mla, Mlb) randomized to low- or high-dose adjuvant lpilimumab (ipi) versus high­dose interferon alfa-2b {HDI): Health-related quality of life {HRQL) analysis of ECOG-ACRIN E1609

Authors
A Tarhini;Y Zheng;S Lee;F Hodi;U Rao;G Cohen;V Sondak;J Kirkwood;L Wagner
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr e22078); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), publication only
Year
2020
Research Committee(s)
Melanoma
Study Number(s)
CTSU/E1609